Sterigenics International, a provider of contract sterilization, gamma technologies and medical isotopes, announced that an affiliate of Warburg Pincus, a global private equity firm focused on growth investing, will recapitalize Sterigenics in partnership with private equity firm GTCR. Terms of the transaction were not disclosed. GTCR purchased Sterigenics in 2011. The transaction is expected to close in the second quarter of 2015. Warburg Pincus' portion of the equity for the recapitalization will come from Warburg Pincus Private Equity XI, L.P.  Operating out of 43 facilities in 12 countries across the Americas, Europe and Asia, Sterigenics provides contract sterilization and ionization services for the medical device, pharmaceutical, food safety, and high-performance materials industries. T

In 2014, Sterigenics acquired Nordion, a provider of Cobalt-60, an isotope that produces gamma radiation and is a critical component of the gamma sterilization process to create a vertically integrated sterilization services company. The acquisition of Nordion expanded the Sterigenics product portfolio, service offering, and global footprint. Additional acquisitions in 2014 included the Florida-based gamma irradiation operator, FTSI, as well as Gammarad, an Italy-based gamma irradiation sterilization company, which now serves as the company's second gamma sterilization facility in Western Europe. In February, Nordion reached landmark partnership agreements with General Atomics and the University of Missouri Research Reactor Center (MURR) to establish a new, long-term supply of medical isotopes. Achieving a long-term supply of medical isotopes for global customers has been a strategic priority of Sterigenics since its acquisition of Nordion.